Anticoagulation for Paraplegic Patients

Introduction to Anticoagulation

The American College of Chest Physicians recommends that paraplegic patients receive prophylactic anticoagulation with low-molecular-weight heparin (LMWH), fondaparinux, or unfractionated heparin to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as paraplegia represents a persistent risk factor for venous thromboembolism 1, 2.

Paraplegia creates a chronic, persistent risk factor for venous thromboembolism due to immobility and venous stasis in the lower extremities 1.
The loss of the muscle pump mechanism that normally facilitates venous return contributes to the risk of venous thromboembolism in paraplegic patients 2.
Paraplegic patients have a potential for recurrent VTE given the ongoing nature of the risk factor 2.

The American College of Chest Physicians recommends LMWH as the preferred agent for VTE prophylaxis in acute spinal cord injury patients, including those with paraplegia 1.
Fondaparinux or unfractionated heparin are acceptable alternatives if LMWH is contraindicated 1.
The duration of prophylaxis should extend beyond acute hospitalization given the persistent nature of immobility risk 3, 4.

The American College of Chest Physicians recommends initiating therapeutic anticoagulation immediately with LMWH, fondaparinux, IV unfractionated heparin, or SC unfractionated heparin if a paraplegic patient develops DVT or PE 1.
Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, dabigatran, or edoxaban are preferred over vitamin K antagonists for long-term treatment 5.
A minimum of 3 months of therapeutic anticoagulation is required for all patients with proximal DVT or PE 3, 5.

DOACs (rivaroxaban, apixaban, dabigatran, or edoxaban) are preferred over warfarin for patients without cancer 5.
These agents offer equivalent efficacy with lower bleeding risk compared to vitamin K antagonists 5.
Warfarin with target INR 2.0-3.0 (target 2.5) is recommended if DOACs are contraindicated or unavailable 3, 8.

Bleeding risk assessment must account for potential falls, pressure ulcers, and autonomic dysreflexia 3.

For VTE prevention in paraplegic patients, initiate LMWH prophylaxis at the time of spinal cord injury and continue throughout acute hospitalization 1.
Transition to extended prophylaxis if the patient remains immobile at discharge 3.
Encourage early mobilization and physical therapy when safe 1.
For VTE treatment in paraplegic patients, start therapeutic anticoagulation immediately (LMWH or DOAC) and continue for a minimum of 3 months 5, 1, 3.
At 3 months, assess bleeding risk formally, and extend anticoagulation indefinitely for low or moderate bleeding risk 2, 6.
If extending therapy, reassess annually 3, 7.